home / stock / oprx / oprx news


OPRX News and Press, OptimizeRx Corporation From 08/10/22

Stock Information

Company Name: OptimizeRx Corporation
Stock Symbol: OPRX
Market: NASDAQ
Website: optimizerx.com

Menu

OPRX OPRX Quote OPRX Short OPRX News OPRX Articles OPRX Message Board
Get OPRX Alerts

News, Short Squeeze, Breakout and More Instantly...

OPRX - OptimizeRx stock sinks 26% on Q2 miss, while FY22 outlook cut on life sciences sector woes

OptimizeRx ( NASDAQ: OPRX ) stock slumped ~26% premarket on Aug. 10 after Q2 results missed estimates and the company lowered its FY22 outlook, seen below analysts' expectations, citing temporary challenges to life sciences industry. Q2 Non-GAAP EPS declined 60%...

OPRX - OptimizeRx Corporation (OPRX) Q2 2022 Earnings Call Transcript

Image source: The Motley Fool. OptimizeRx Corporation (NASDAQ: OPRX) Q2 2022 Earnings Call Aug 09, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: OptimizeRx Corporation (OPRX) Q2 2022 Earnings Call Transcript

OPRX - OptimizeRx Corporation (OPRX) CEO William Febbo on Q2 2022 Results - Earnings Call Transcript

OptimizeRx Corporation (OPRX) Q2 2022 Earnings Conference Call August 09, 2022 4:30 PM ET Company Participants William Febbo - CEO and Director Ed Stelmakh - CFO and COO Stephen Silvestro - Chief Commercial Officer Conference Call Participants Ryan Da...

OPRX - OptimizeRx Q2 Non-GAAP EPS, revenue misses, FY22 guidance below consensus

OptimizeRx press release ( NASDAQ: OPRX ): Q2 Non-GAAP EPS of $0.04 (vs. $0.10 Y/Y) misses by $0.05 . Revenue of $14M (+2.9% Y/Y) misses by $3.06M . For FY22, net revenue is expected to be in the range of of $62M to $68M (vs. consensus of $81.47M) For fur...

OPRX - OptimizeRx Reports Second Quarter 2022 Financial Results, Innovative Platform Expansions Now Extends Reach to HCPs Across Social Media and Patients at Point-of-Dispense

Revenue Up 3% to $14.0 million, driven by new customer and program launches Increase in breadth and scope of brand deal size represents further momentum in the validation of our value proposition Generated $4.4 million in cash flow from operations during the first half of 2022 ...

OPRX - OptimizeRx extends reach with Cooler Screens Partnership

OptimizeRx ( NASDAQ: OPRX ) has announced a partnership with Cooler Screens, a media and merchandising platform that brings the best aspects of in-store digital advertising into the retail brick-and-mortar consumer experience. This new offering will enhance the value agen...

OPRX - OptimizeRx Extends Omnichannel Reach With Cooler Screens Partnership

ROCHESTER, Mich., July 26, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy today announced a partnership with Cooler Screens, a media and merc...

OPRX - OptimizeRx Sets Second Quarter Fiscal 2022 Conference Call for Tuesday, August 9 at 4:30 p.m. ET

ROCHESTER, Mich., July 21, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp . (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, will hold a conference call on Tuesday, August 9, 2022,...

OPRX - CRMD, CALA and TBLT among mid-day movers

Gainers: Direct Digital Holdings ( DRCT ) +81% . ToughBuilt Industries ( TBLT ) +54% . Stronghold Digital Mining ( SDIG ) +42% . Calithera Biosciences ( CALA ) +27% . CorMedix ( CRMD ) +23% . Allakos ( ALLK ) +22% ...

OPRX - Rhythm, Allakos top healthcare gainers; Vascular, Belite lead losers' pack

Gainers: Rhythm Pharmaceuticals ( RYTM ) +20% . Allakos ( ALLK ) +14% . Senti Biosciences ( SNTI ) +13% . Arcturus Therapeutics ( ARCT ) +7% . Verve Therapeutics ( VERV ) +5% . Losers: Vascular Biogenics ( VBLT ) -78%...

Previous 10 Next 10